Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status - Service de recherche sur les effets biologiques et Sanitaires des rayonnements ionisants - IRSN/PSE-SANTE/SESANE Accéder directement au contenu
Article Dans Une Revue Journal of Endocrinological Investigation Année : 2024

Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status

Résumé

Purpose: Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed. The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score. Methods: All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed. Each case was matched randomly with at least four RAI-avid DTC control patients based on histological and clinical criteria. Conditional logistic regression was used to examine the association between RAIR-disease and variables with univariate and multivariate analyses. A risk score was then developed from the multivariate conditional logistic regression model to predict the risk of refractory disease occurrence. The optimal cut-off value for predicting the occurrence of RAIR-TC was assessed by receiver operating characteristic (ROC) curves and Youden's statistic. Results: We analyzed 159 RAIR-TC cases for a total of 759 controls and found 7 independent risk factors for predicting RAIR-TC occurrence: age at diagnosis ≥ 55, vascular invasion, synchronous cervical, pulmonary and bone metastases at initial work-up, cervical and pulmonary recurrence during follow-up. The predictive score of RAIR-disease showed a high discrimination power with a cut-off value of 8.9 out of 10 providing 86% sensitivity and 92% specificity with an area under the curve (AUC) of 0.95. Conclusion: Predicting the occurrence of RAIR-disease in DTC patients may allow clinicians to focus on systemic redifferentiating strategies and/or local treatments for metastatic lesions rather than pursuing with ineffective RAI-therapies.
Fichier principal
Vignette du fichier
Schubert_2024.pdf (835.07 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

irsn-04581312 , version 1 (21-05-2024)

Licence

Identifiants

Citer

L Schubert, Murielle Mbekwe-Yepnang, J. Wassermann, Y Braik-Djellas, L Jaffrelot, et al.. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. Journal of Endocrinological Investigation, 2024, Online ahead of print. ⟨10.1007/s40618-024-02352-z⟩. ⟨irsn-04581312⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More